{"id":710661,"date":"2013-03-26T11:00:15","date_gmt":"2013-03-26T05:30:15","guid":{"rendered":"http:\/\/stockviz.biz\/index.php\/?p=710661"},"modified":"2013-03-26T11:00:15","modified_gmt":"2013-03-26T05:30:15","slug":"analysis-colpal-2","status":"publish","type":"post","link":"https:\/\/stockviz.biz\/index.php\/2013\/03\/26\/analysis-colpal-2\/","title":{"rendered":"Analysis: COLPAL"},"content":{"rendered":"<p>Colgate-Palmolive [stockquote]COLPAL[\/stockquote] investors have had a tough 2013. After hitting an all-time high of Rs.\u00a01580, the stock has slid to Rs.\u00a01250 levels &#8211; a whopping 21% drop. Investors have been worried about falling sales in spite of holding prices steady and the imminent entry of P&amp;G into the oral-care market. That said, Colgate holds over 54% of the toothpaste market and has been busy expanding its\u00a0distribution and marketing into rural areas where\u00a0per capita consumption of toothpaste is half that of urban areas.<\/p>\n<p><a href=\"http:\/\/stockviz.biz\/Equity?TICKER=COLPAL\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-710691\" alt=\"COLPAL Technical Chart\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/35a2df6eb315492c97a19c6f4ea11070634998893728767004.png\" width=\"745\" height=\"950\" srcset=\"https:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/35a2df6eb315492c97a19c6f4ea11070634998893728767004.png 745w, https:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/35a2df6eb315492c97a19c6f4ea11070634998893728767004-235x300.png 235w\" sizes=\"auto, (max-width: 745px) 100vw, 745px\" \/><\/a><\/p>\n<p>We were a <a title=\"Colgate Palmolive Analysis\" href=\"http:\/\/stockviz.biz\/index.php\/?p=309721\" target=\"_blank\">short-term <strong>buy<\/strong><\/a>\u00a0back in February. However, the technicals this time are giving mixed signals. Our 4-9-18 model has been flipping between buy and sell all of this month and <a title=\"Aroon technical indicator\" href=\"http:\/\/stockviz.biz\/index.php\/technical-trading\/aroon\/\" target=\"_blank\">Aroon <\/a>is stuck in neutral. However, <a title=\"Relative Strength Indiex\" href=\"http:\/\/stockviz.biz\/index.php\/part-ix-relative-strength-index-rsi\/\" target=\"_blank\">RSI <\/a>levels seem to be headed toward over-sold levels, suggesting a bounce from support at Rs. 1250 levels is possible.<\/p>\n<p>The stock does pay a fair amount of dividend &#8211; Rs. 8\/share was recently announced and given that its in the FMCG space, it is more-or-less recession proof. An extremely low beta of 0.16 provides a certain measure of comfort during volatile times.<\/p>\n<p><a href=\"http:\/\/stockviz.biz\/Equity?TICKER=COLPAL\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-710881\" alt=\"COLPAL quarterly results\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/quarterly.png\" width=\"782\" height=\"348\" srcset=\"https:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/quarterly.png 782w, https:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/quarterly-300x133.png 300w, https:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/quarterly-500x222.png 500w\" sizes=\"auto, (max-width: 782px) 100vw, 782px\" \/><\/a><\/p>\n<p>We would be buyer&#8217;s if the stock can hold on to its Rs. 1250 support levels over the next few days. Otherwise the next support is around Rs. 1200. This is a good stock to own for long-term buy-and-hold investors at these levels.<\/p>\n<h6 class=\"zemanta-related-title\" style=\"font-size: 1em\">Related articles<\/h6>\n<ul class=\"zemanta-article-ul zemanta-article-ul-image\" style=\"margin: 0;padding: 0;overflow: hidden\">\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"padding: 0;background: none;float: left;vertical-align: top;text-align: left;width: 84px;font-size: 11px;margin: 2px 10px 10px 2px\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/stockviz.biz\/2013\/03\/22\/analysis-shoperstop\/\" target=\"_blank\"><img decoding=\"async\" style=\"padding: 0;margin: 0;border: 0;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/154213412_80_80.jpg\" \/><\/a><a style=\"overflow: hidden;text-decoration: none;line-height: 12pt;height: 80px;padding: 5px 2px 0 2px\" href=\"http:\/\/stockviz.biz\/2013\/03\/22\/analysis-shoperstop\/\" target=\"_blank\">Analysis: SHOPERSTOP<\/a><\/li>\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"padding: 0;background: none;float: left;vertical-align: top;text-align: left;width: 84px;font-size: 11px;margin: 2px 10px 10px 2px\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/www.rediff.com\/business\/report\/glaxosmithkline-back-on-health-track\/20130315.htm\" target=\"_blank\"><img decoding=\"async\" style=\"padding: 0;margin: 0;border: 0;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/152449827_80_80.jpg\" \/><\/a><a style=\"overflow: hidden;text-decoration: none;line-height: 12pt;height: 80px;padding: 5px 2px 0 2px\" href=\"http:\/\/www.rediff.com\/business\/report\/glaxosmithkline-back-on-health-track\/20130315.htm\" target=\"_blank\">GlaxoSmithKline back on health track<\/a><\/li>\n<\/ul>\n<div class=\"zemanta-pixie\" style=\"margin-top: 10px;height: 15px\"><img decoding=\"async\" class=\"zemanta-pixie-img\" style=\"border: none;float: right\" alt=\"\" src=\"http:\/\/img.zemanta.com\/pixy.gif?x-id=56b97bd8-4e9d-4c12-8ca7-81b40daa176a\" \/><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Colgate-Palmolive [stockquote]COLPAL[\/stockquote] investors have had a tough 2013. After hitting an all-time high of Rs.\u00a01580, the stock has slid to Rs.\u00a01250 levels &#8211; a whopping 21% drop. Investors have been worried about falling sales in spite of holding prices steady and the imminent entry of P&amp;G into the oral-care market. That said, Colgate holds over &hellip; <\/p>\n","protected":false},"author":4,"featured_media":710861,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[693,815],"class_list":["post-710661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-your-money","tag-colpal","tag-technical-analysis","entry"],"_links":{"self":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts\/710661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/comments?post=710661"}],"version-history":[{"count":0,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts\/710661\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/media\/710861"}],"wp:attachment":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/media?parent=710661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/categories?post=710661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/tags?post=710661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}